恩替卡韦治疗慢性乙型肝炎患者疗效观察

目的观察恩替卡韦治疗CHB患者的疗效。方法 43例HBeAg阳性和18例HBeAg阴性患者接受恩替卡韦治疗,比较两组治疗24周和48周时的疗效。结果在治疗24周时,HBeAg阳性组HBV DNA转阴15例（34.9%）4,8周时转阴28例（65.1%）,而HBeAg阴性组分别转阴15例（83.3%）和17例（94.4%,P=0.001和0.018）;两组在24周和48周时ALT复常率均无显著性差异（P=0.713和0.138）;在34例HBV DNA定量〉10^7copies/ml与27例HBV DNA定量〈107copies/ml两组中,治疗24周时,HBV DNA转阴例数分别为11例（32%）和19例（70%,P=0.03）,治疗48周时,则分别为23例（68%）和22例（81%,P=0.22）。结论本研究提示恩替卡韦治疗CHB有很好的抗病毒活性。

The efficacy of entecavir in the treatment of patients with hepatitis B

Objective To evaluate the efficacy of entecavir in the treatment of patients with chronic hepatitis B.Methods 43 patients with HBeAg positive and 18 with HBeAg negative were treated with entecavir for 48 weeks.Results The HBV DNA negative rates in the HBeAg negative group were 83.3% and 94.4%,higher than 34.9% and 65.1% in the HBeAg positive group at week 24 and week 48（P=0.001 and 0.018,respectively）,while the ALT normalization rates between the two groups had no significant difference（P=0.713 and 0.138）;in 34 patients with serum HBV DNA1×107 copies/ml and 27 with serum HBV DNA〈1×10^7copies/ml,the HBV DNA negative rates at week 24 were 32% and 70%,respectively（P=0.03）,while those at week 48 were 68% and 81%,respectively（P=0.22）.Conclusions Entecavir has significant anti-viral activity in the treatment of patients with CHB.